Somatostatin-Immunoreactive Pancreaticoduodenal Neuroendocrine Neoplasms: Twenty-Three Cases Evaluated according to the WHO 2010 Classification

2015 ◽  
Vol 103 (5) ◽  
pp. 567-577 ◽  
Author(s):  
Iben Engelund Luna ◽  
Nina Monrad ◽  
Tina Binderup ◽  
Christina Boisen Thoegersen ◽  
Linda Hilsted ◽  
...  
Keyword(s):  
Neuroendocrine Neoplasms ◽  
Who 2010 Classification

scholarly journals Is There a Need for New Classifications to Predict Prognosis in Gastroenteropancreatic Neuroendocrine Carcinomas?

2021 ◽  
Author(s):  
Emel Tekin ◽  
Arzu Avcı ◽  
Neşe Ekinci
Keyword(s):  
Survival Rates ◽  
Case Series ◽  
Threshold Value ◽  
World Health ◽  
Proliferation Index ◽  
Neuroendocrine Neoplasms ◽  
Ki 67 ◽  
Significant Difference ◽  
Who 2010 Classification ◽  
Health Organization

Objective: Neuroendocrine neoplasms (NEN) are frequently located in the lung and gastroenteropancreatic (GEP) system organs. Neuroendocrine carcinoma (NEC) constitutes 5% of GEP NENs and has a very high malignancy potential. In this study, it is aimed to determine a new threshold value in addition to the 20% Ki-67 proliferation index that was specified as a threshold value for predicting survival in patients with grade (G) 3 tumors according to World Health Organization (WHO) 2010 classification. Method: Demographic, clinicopathologic features and survival rates of 34 patients diagnosed with GEP NEC between 2008-2015 in İzmir Katip Celebi University Atatürk Training and Research Hospital Medical Pathology Clinic were evaluated retrospectively. Results: Most of the 34 (76.5%) cases were male and the average age was 63.9 years. Median survival rates were 15, and 7 months in patients with Ki-67 indexes of ≤65% and >65%, respectively (p=0.232). Conclusion: Recent studies have shown heterogeneity of high-grade NENs, identified as NEC and foreseen their subdivision into biological subgroups. The researchers suggest that the NECs should be divided into two categories as patients with Ki-67 indexes of 20-55% and >55%. In our study, the most significant difference in survival rates was observed when 65% was selected as threshold value for Ki-67 index which supports the results of other studies in the literature. Since the number of our cases is limited and it is a single-center study, the findings obtained needs to be further investigated in studies with greater number of case series.

scholarly journals Pancreatic Neuroendocrine Neoplasms: Basic Biology, Current Treatment Strategies and Prospects for the Future

2016 ◽  
Author(s):  
Akihiro Ohmoto ◽  
Hirofumi Rokutan ◽  
Shinichi Yachida
Keyword(s):  
Treatment Strategies ◽  
Genomic Analysis ◽  
Genetic Alterations ◽  
Current Treatment ◽  
Pancreatic Tumors ◽  
Proliferation Index ◽  
Neuroendocrine Neoplasms ◽  
Ki 67 ◽  
Pancreatic Neuroendocrine Neoplasms ◽  
Who 2010 Classification

Pancreatic neuroendocrine neoplasms (pNENs) are rare tumors accounting for only 1-2% of all pancreatic tumors. pNENs are pathologically heterogeneous and are categorized into three groups (neuroendocrine tumor: NET G1, NET G2 and neuroendocrine carcinoma: NEC) on the basis of Ki-67 proliferation index and mitotic count according to the 2010 WHO classification of gastroenteropancreatic NENs. NEC in this classification includes both histologically well-differentiated and poorly differentiated subtypes, and modification of the WHO 2010 classification is under discussion based on genetic and clinical data. Genomic analysis has revealed NETs G1/G2 have genetic alterations in chromatin remodeling genes such as MEN1, DAXX and ATRX, whereas NECs have an inactivation of TP53 and RB1, and these data suggest that different treatment approaches would be required for NET G1/G2 and NEC. While there are promising molecular targeted drugs, such as everolimus or sunitinib, for advanced NET G1/G2, treatment stratification based on appropriate predictive and prognostic biomarkers is becoming an important issue. The clinical outcome of NEC is still dismal, and a more detailed understanding of the genetic backround together with preclinical studies to develop new agents, including those already under investigation for SCLC, will be needed to improve the prognosis.

scholarly journals Gastroenteropancreatic Neuroendocrine Neoplasia Characterization in Portugal: Results from the NETs Study Group of the Portuguese Society of Endocrinology, Diabetes and Metabolism

2019 ◽  
Vol 2019 ◽  
pp. 1-10 ◽  
Author(s):  
A. P. Santos ◽  
J. Vinagre ◽  
P. Soares ◽  
I. Claro ◽  
A. C. Sanches ◽  
...  
Keyword(s):  
Large Scale ◽  
Somatostatin Analogues ◽  
Cross Sectional Study ◽  
National Database ◽  
Neuroendocrine Neoplasms ◽  
Cross Sectional ◽  
Multicentric Study ◽  
Large Scale Data ◽  
Poorly Differentiated ◽  
Who 2010 Classification

Background. The incidence of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) has been increasing in the last five decades, but there is no large-scale data regarding these tumours in Portugal. We conducted a cross-sectional, multicentric study in main Portuguese centers to evaluate the clinical, pathological, and therapeutic profile of GEP-NENs. Methods. From November, 2012, to July, 2014, data from 293 patients diagnosed with GEP-NENs from 15 centers in Portugal was collected and registered in an online electronic platform. Results. Median age at diagnosis was 56.5 (range: 15-87) years with a preponderance of females (54.6%). The most frequent primary sites were the pancreas (31.1%), jejunum-ileum (24.2%), stomach (13.7%), and rectum (8.5%). Data regarding hormonal status was not available in most patients (82.3%). Stratified by the tumour grade (WHO 2010 classification), we observed 64.0% of NET G1, 24.7% of NET G2, and 11.3% of NEC. Poorly differentiated tumours occurred mainly in older patients (p=0.017), were larger (p<0.001), and presented more vascular (p=0.004) and lymphatic (p=0.001) invasion. At the time of diagnosis, 44.4% of GEP-NENs presented metastatic disease. Surgery (79.6%) and somatostatin analogues (30.7%) were the most frequently used therapies of GEP-NENs with reported grading. Conclusion. In general, Portuguese patients with GEP-NENs presented similar characteristics to other populations described in the literature. This cross-sectional study represents the first step to establish a national database of GEP-NENs that may aid in understanding the clinical and epidemiological features of these tumours in Portugal.

Chest metastases in advanced small bowel neuroendocrine neoplasms: incidence and outcome

2018 ◽  
Author(s):  
Jasryan Birk ◽  
Ben Jacobs ◽  
James Bailey ◽  
Besma Musaddaq ◽  
Conrad Von Stempel ◽  
...  
Keyword(s):  
Small Bowel ◽  
Neuroendocrine Neoplasms

Liver embolisation for patients diagnosed with neuroendocrine neoplasms: systematic review and meta-analysis of the literature

2019 ◽  
Author(s):  
Rahul Kanabar ◽  
Jorge Barriuso ◽  
Mairead McNamara ◽  
Was Mansoor ◽  
Richard Hubner ◽  
...  
Keyword(s):  
Systematic Review ◽  
Meta Analysis ◽  
Neuroendocrine Neoplasms

Neuroendocrine neoplasms: experiences of a single tertiary referral endocrine centre in Hungary

2019 ◽  
Author(s):  
Judit Tőke ◽  
Karoly Pocsai ◽  
Judit Major ◽  
Reka Kollar ◽  
Reka Szatmari ◽  
...  
Keyword(s):  
Neuroendocrine Neoplasms ◽  
Tertiary Referral

Sporadic neuroendocrine neoplasms in young-adult patients: Differences in natural history, prognosis and treatment compared to adult-elderly patients

2020 ◽  
Author(s):  
Barbara Altieri ◽  
Roberta Modica ◽  
Filomena Bottiglieri ◽  
Cicco Federica de ◽  
Antongiulio Faggiano ◽  
...  
Keyword(s):  
Young Adult ◽  
Natural History ◽  
Elderly Patients ◽  
Adult Patients ◽  
Neuroendocrine Neoplasms
Sign in / Sign up

Export Citation Format

Share Document